Welcure Drugs Peer Comparison

BSE: 524661

₹0.23

₹-0.01 (-4.17%)

As on 03-Sep-2026IST

Market cap

₹28 Cr

Revenue (TTM)

₹366 Cr

P/E Ratio

--

P/B Ratio

0.3

Div. Yield

0 %

Edit

	Welcure Drugs	Entero Health	Bio Medica Laboratories	VijayPD Ceutical	Speciality Medicines
Market cap (₹ Cr)	28	8,041	204	137	127
Revenue (₹ Cr)	366	7,128	38	107	58
Net Profit (₹ Cr)	-16.99	167.66	9.79	4.80	8.61
Net Margin (%)	-4.63	2.35	25.56	4.46	14.70
RoE (%)	-14.35	7.58	99.59	14.91	37.85
Price to Earnings	--	64.12	17.01	27.30	9.78
Price-To-Book	0.29	4.64	--	--	1.79

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Welcure Drugs	Entero Health	Bio Medica Laboratories	VijayPD Ceutical	Speciality Medicines
Operating Revenue	24.55	5,095.78	38.20	106.81	58.27
Total Income	26.46	5,135.29	38.33	107.59	58.54
Total Expenditure	23.58	4,924.23	22.82	98.22	49.14
EBITDA	0.97	171.55	15.37	8.59	9.13
Depreciation	0.01	30.69	1.01	0.69	0.20
EBIT	0.96	140.86	14.37	7.90	8.93
Interest	0.09	41.62	1.35	2.15	0.51
Other Income	1.91	39.51	0.13	0.78	0.27
Exceptional Items	--	--	--	--	--
Profit before Tax	2.78	138.74	13.14	6.52	8.69
Provision for Tax	0.61	31.31	3.35	1.73	0.08
Profit after Tax	2.17	107.43	9.79	4.80	8.61

Liabilities (₹ Cr)

	Welcure Drugs	Entero Health	Bio Medica Laboratories	VijayPD Ceutical	Speciality Medicines
Shareholder's Funds	102.51	1,724.15	14.73	32.17	30.42
Minority Interest	--	46.21	--	--	--
Non-Current Liabilities	123.20	72.84	7.17	0.47	2.77
Current Liabilities	41.27	845.02	16.99	24.46	6.80
Total Liabilities	266.98	2,702.52	39.12	57.15	39.98

Assets (₹ Cr)

	Welcure Drugs	Entero Health	Bio Medica Laboratories	VijayPD Ceutical	Speciality Medicines
Non-Current Assets	84.84	612.51	7.81	10.70	3.56
Current Assets	182.14	2,075.71	31.09	46.40	36.42
Total Assets	266.98	2,702.52	39.12	57.15	39.98
Total Debt*	123.20	298.81	15.01	21.77	5.05
Net Current Assets	140.87	1,230.69	14.10	21.95	29.62
Contingent Liabilities	--	4.01	0.05	0.39	--

Cashflow (₹ Cr)

	Welcure Drugs	Entero Health	Bio Medica Laboratories	VijayPD Ceutical	Speciality Medicines
Cash From Operating Activities	-222.03	-76.87	-3.67	-7.89	-5.79
Cash Flow from Investing Activities	-0.06	219.80	0.34	-0.55	-2.07
Cash from Financing Activities	222.20	-73.66	3.33	-2.38	8.46
Net Cash Inflow / Outflow	0.11	69.27	0.00	-10.82	0.60

Ratios

Profitability Ratios

	Welcure Drugs	Entero Health	Bio Medica Laboratories	VijayPD Ceutical	Speciality Medicines
ROCE (%)	2.53	9.16	64.18	16.08	34.47
ROE (%)	4.18	6.40	99.59	14.91	37.85
ROA (%)	1.62	4.29	33.60	8.40	27.50
EBIT Margin (%)	11.72	4.14	40.59	8.77	16.13
Net Margin (%)	8.20	2.09	25.56	4.46	14.70
Cash Profit Margin (%)	8.87	2.71	28.28	5.14	15.11

Growth Ratios

	Welcure Drugs	Entero Health	Bio Medica Laboratories	VijayPD Ceutical	Speciality Medicines
Revenue Growth (%)	--	29.92	150.47	0.00	111.71
EBIT Growth (%)	2,172.91	67.16	170.72	--	73.88
Net Profit Growth (%)	1,341.48	169.94	292.00	0.00	193.43
EPS Growth (%)	248.31	142.37	292.00	0.00	133.30
Book Value Growth (%)	7,547.19	5.11	198.35	0.00	101.92

Valuation Ratios

	Welcure Drugs	Entero Health	Bio Medica Laboratories	VijayPD Ceutical	Speciality Medicines
Price / Earnings	4.28	52.15	0.00	0.00	0.00
Price / Book Value	1.00	2.88	0.00	0.00	0.00
Dividend Yield (%)	0.00	0.00	--	--	--
EV/EBITDA	78.30	23.61	1.56	3.49	1.13
Market Cap (₹ Cr)	102.21	4,944.94	0.00	0.00	0.00

Solvency Ratios

	Welcure Drugs	Entero Health	Bio Medica Laboratories	VijayPD Ceutical	Speciality Medicines
Debt to Equity	1.20	0.17	1.02	0.68	0.17
Short term debt to equity ratio	--	0.17	0.43	0.64	0.04
Current Ratio	4.41	2.46	1.83	1.90	5.36
Quick Ratio	0.94	1.68	0.76	1.43	2.80
Interest Coverage	32.06	4.33	10.70	4.03	18.03

Operating Efficiency Ratios

	Welcure Drugs	Entero Health	Bio Medica Laboratories	VijayPD Ceutical	Speciality Medicines
Debtors to sales (%)	77.19	16.30	10.73	22.28	16.45
Asset Turnover	0.18	2.03	1.31	1.87	1.86
Receivable days	281.74	51.78	30.75	81.32	63.57
Inventory Days	2,133.85	38.71	121.86	39.42	79.57
Payable days	51.58	24.83	117.74	8.63	14.65
Cash Conversion Cycle	2,364.01	65.66	34.88	112.12	128.49

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.